A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis

Health Care–Associated Native Valve Endocarditis: Importance of Non-nosocomial Acquisition

(2013) Natividad Benito   ANNALS OF INTERNAL MEDICINE

Evaluation of Standard- and High-Dose Daptomycin versus Linezolid against Vancomycin-Resistant Enterococcus Isolates in anIn VitroPharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations

(2012) Ashley D. Hall et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

High-Dose Daptomycin for Cardiac Implantable Electronic Device-Related Infective Endocarditis

(2011) E. Durante-Mangoni et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary

(2011) Catherine Liu et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

(2011) Catherine Liu et al.   CLINICAL INFECTIOUS DISEASES

Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets

(2011) R. Kullar et al.   CLINICAL INFECTIOUS DISEASES

High-Dose Daptomycin for Treatment of Complicated Gram-Positive Infections: A Large, Multicenter, Retrospective Study

(2011) Ravina Kullar et al.   PHARMACOTHERAPY

Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy

(2009) Pamela A Moise et al.   ANNALS OF PHARMACOTHERAPY

Relationship between Susceptibility to Daptomycin In Vitro and Activity In Vivo in a Rabbit Model of Aortic Valve Endocarditis

(2009) H. F. Chambers et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety of High‐Dose Intravenous Daptomycin Treatment: Three‐Year Cumulative Experience in a Clinical Program

(2009) D. A. Figueroa et al.   CLINICAL INFECTIOUS DISEASES

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin® Outcomes Registry and Experience (CORE)

(2009) John F. Mohr et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations

(2008) W. E. Rose et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Contemporary Epidemiology and Prognosis of Health Care–Associated Infective Endocarditis

(2008) Nuria Fernández‐Hidalgo et al.   CLINICAL INFECTIOUS DISEASES

Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job’s syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin

(2008) Burke A. Cunha et al.   HEART & LUNG

A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria

(2008) D. E. Katz et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE